China Medical Device QMS

Adapting your medical device QMS (Quality Management System) to meet China’s regulatory requirements is challenging but essential to obtain market approval and ensure ongoing compliance.

The National Medical Products Administration (NMPA), which succeeded the China Food and Drug Administration, is the authority responsible for ensuring that devices and IVDs on the market are fully compliant. To strengthen oversight, the NMPA released the 58th Announcement on December 12th, 2014, focusing on the implementation of Good Supplier Practices (GSP) for medical device distributors. These regulatory requirements apply across the entire product lifecycle to safeguard patient health and product performance.

This means that IVD and Medical Device QMS as well as overall compliance will be checked at various stages throughout their lifecycle.

Medical Device Regulations
Quality Management Requirements

Full Lifecycle QMS Checks

Understanding how these obligations translate into concrete checkpoints is critical, as compliance will 
be verified at multiple stages before and after market entry.

Product Registration – The IVD or medical device QMS will be reviewed as part of the registration submission application process.
Clinical Evaluation & Testing – Higher risk devices may require clinical trials or clinical evaluation reports (CERs) to demonstrate compliance with Chinese safety and performance standards.
Annual Reporting & Renewals – Class II and III medical devices and Class B to D IVDs require annual reports. These must include information on imports and any product recalls or quality management issues. As such, registrations must be renewed every five years, any quality issues will be highlighted for review. High-risk devices are subject to stringent regulations and random inspections by the NMPA to ensure safety and quality standards are met. Thorough due diligence is necessary to comply with these specific requirements.
Importation & Customs Clearance – Devices must include Chinese-language labeling, user instructions, and mandatory symbols following GB standards. This will be checked upon import.
Post-Market Surveillance & Adverse Event Reporting – Once the IVD or device is approved, manufacturers and local agents must establish tracking, monitoring, and reporting systems for IVD or medical device safety and effectiveness.
Factory Inspections – These may be required as part of the registration process or they may be requested as part of the NMPA annual inspection plan. Such inspections, including overseas inspections for overseas manufacturers, will verify that the product is manufactured in compliance with China’s Medical Device Good Manufacturing Practice (GMP) standards.

Quality Management System Requirements

The Quality Management System (QMS) is a cornerstone of medical device and IVD regulations. The NMPA mandates that medical device manufacturers establish and maintain a QMS that not only meets ISO 13485 standards but also incorporates specific Chinese quality management standards. This comprehensive system must cover the entire product lifecycle, from initial design and development to production, quality control, and post-market surveillance.

Medical device manufacturers are required to conduct regular audits and self-inspections to ensure adherence to quality management and identify areas for improvement. The QMS must include detailed procedures for risk management, adverse event reporting, and post-market surveillance, as well as stringent document control and record-keeping practices. By implementing a robust QMS, manufacturers can fully comply with China’s medtech and IVD regulations, maintain high standards of quality and safety, and ultimately protect patient health.

In summary, well-implemented quality management is not just a regulatory requirement but a critical component in the lifecycle of devices, ensuring they meet the highest standards of safety and effectiveness in the Chinese market.

In vitro diagnostic reagents quality management

Our Quality Management Systems Services

We provide end-to-end support to achieve compliance for your Quality Management Systems (QMS) and Good Manufacturing Practices (GMP) to ensure you meet all regulatory requirements.

QMS Gap Analysis & Adaptation

Detailed assessment of your existing ISO 13485 system against NMPA medical device and IVD GMP requirements
Identification of gaps and development of an implementation roadmap
Alignment with China-specific risk management, production controls, and supplier oversight requirements

Document Preparation & Compliance Support

Development and optimization of SOPs (Standard Operating Procedures), work instructions, and quality records to meet NMPA requirements.
Support for establishing and maintaining a Product Technical Requirement (PTR) document, essential for registration and post-market compliance.
Assistance with change control procedures, ensuring smooth implementation of product modifications.

Supplier Qualification & Quality Control

Guidance on supplier qualification and audits to meet China’s GMP and international standards.
Implementation of supplier quality agreements, ensuring main raw materials and components comply with regulatory expectations.
Risk assessment and monitoring of critical suppliers and contract manufacturers.

Production Process Compliance

Implementation of process validation protocols aligned with China’s medical device GMP requirements.
Guidance on establishing corrective and preventive action (CAPA) procedures to meet NMPA expectations.
Support for product release, adverse event monitoring and reporting, maintaining full traceability and product recall systems for post-market obligations.

Chinese GMP Audits

Complying with China’s GMP requirements is mandatory, often requiring on-site audits by the NMPA. Our team helps domestic and overseas manufacturers prepare for and pass these audits with a structured and efficient approach.

GMP Audit Preparation & Mock Inspections

Comprehensive audit readiness assessment to identify gaps before official NMPA inspections.
Mock audits simulating NMPA inspection protocols to ensure preparedness. Conducting a mock overseas inspection helps manufacturers identify and address potential issues before the actual regulatory audit.
Corrective action planning based on common NMPA published findings and industry best practices.
Regular self-inspections are required for enterprises operating Class II and Class III medical devices, with annual self-inspection reports submitted to local drug supervision authorities.

On-Site & Remote NMPA Inspection Support

Assistance during NMPA on-site overseas inspections to ensure smooth regulatory interaction. On-site inspections are crucial for verifying compliance with the Quality Management System (QMS) and regulatory standards.
Support in addressing auditor queries and documentation requests in real time.
Post-audit follow-up to address any non-conformities and regulatory concerns.

GMP Documentation & Process Compliance

Preparation of Chinese GMP-compliant manufacturing process records, including batch records, validation reports, and risk assessments.
Assistance with Good Distribution Practice (GDP) compliance for companies handling medical device logistics and supply chain operations.
Review and optimization of cleanroom, sterilization, and validation processes to meet Chinese regulatory requirements.

Corrective & Preventive Actions (CAPA) Implementation

Development of CAPA systems to resolve deficiencies identified during audits.
Root cause analysis and action planning to ensure continued compliance.
Ongoing monitoring and updates to maintain NMPA GMP compliance.

If you would like more information on China's Medical Device Good Manufacturing Practices and our services please click here.

Useful Articles

View More

Digital Medical Device Clinical Trials in South Korea: Understanding the MFDS Framework

Understand MFDS clinical trial requirements for digital medical devices, including real-world evidence, data-based studies, and software validation expectations.

June 2, 2026
Digital Medical Device Clinical Trials in South Korea: Understanding the MFDS Framework

Cisema Expands into South Korea

Supporting foreign manufacturers entering South Korea with regulatory services for medical devices, IVDs, and quasi-drugs.

June 1, 2026
Cisema Expands into South Korea
Seoul skyline in the early evening

Indonesia Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know

Learn which products are covered by Indonesia's halal framework, the labeling and manufacturing obligations, and phased compliance timelines.

May 20, 2026
Indonesia Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know
A healthcare worker in a white coat checks a seated patient’s blood pressure while another medical staff member in green scrubs stands nearby holding a clipboard in a bright clinic setting.

Medical Device Market Access for Thailand, Indonesia, and the Philippines

Cisema offers regulatory insight and market access strategy for medical devices in Thailand, Indonesia, and the Philippines.

May 15, 2026
Medical Device Market Access for Thailand, Indonesia, and the Philippines
Medical Device Market Access for Thailand, Indonesia, and the Philippines

Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers

Learn how to register medical devices in Indonesia, including Authorized Representative rules, classification, dossiers, timelines, and fees.

May 15, 2026
Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers
Three masked surgical staff in green operating room attire stand with folded arms beside a patient lying on an operating table, with medical monitors and X-ray images displayed in a dimly lit operating room.”

Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers

Understand the pathway for intraocular lens (IOL) registration in China, including NMPA requirements and key compliance steps.

May 14, 2026
Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers
A close-up of an eye with a transparent intraocular lens held by surgical tweezers positioned in front of the pupil, illustrating ophthalmic medical device use. The visual supports themes of regulatory compliance, product registration, and market access
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Learn more

Drug Device Combination Products

We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

Latest Insights

View More

China NMPA Issues 2026 Medical Device Industry Standards Development and Revision Plan

China’s National Medical Products Administration has issued its 2026 medical device standards plan, introducing 80+ new and revised standards

April 23, 2026
China NMPA Issues 2026 Medical Device Industry Standards Development and Revision Plan

China NMPA Clears 104 Innovative Medical Devices for Special Review in 2025

Learn about the 104 products China’s NMPA admitted into the Special Review Procedure for Innovative Medical Devices in 2025.

March 18, 2026
China NMPA Clears 104 Innovative Medical Devices for Special Review in 2025
China NMPA Clears 104 Innovative Medical Devices for Special Review in 2025

Hong Kong DH Mandates Medical Device Listing for Public Procurement by March 2026

The Department of Health has mandated MDACS listing for public procurement eligibility — see which devices are affected and how to prepare.

April 15, 2026
Hong Kong DH Mandates Medical Device Listing for Public Procurement by March 2026
Hong Kong DH Mandates Medical Device Listing for Public Procurement by March 2026

China Medical Device Imports Remain Stable in H1 2025

China’s H1 medical device imports reached approx. USD 24 billion, showing stable demand amid shifts in key categories and sourcing countries.

March 18, 2026
China Medical Device Imports Remain Stable in H1 2025
China Medical Device Imports Remain Stable in H1 2025

China’s NMPA Releases Draft Adjustments to the IVD Classification Catalogue

NMPA issues draft changes to China’s IVD Classification Catalogue, adding new risk classes and technology platforms.

March 18, 2026
China’s NMPA Releases Draft Adjustments to the IVD Classification Catalogue
China’s NMPA Releases Draft Adjustments to the IVD Classification Catalogue

UDI in China: Most Medical Devices Now Covered Under the Latest NMPA Drafts

Latest NMPA drafts propose expanding Unique Device Identification (UDI) rules to nearly all medical devices by 2029.

March 18, 2026
UDI in China: Most Medical Devices Now Covered Under the Latest NMPA Drafts
UDI in China: Most Medical Devices Now Covered Under the Latest NMPA Drafts
Previous
Previous

Get in Touch with Our Life Sciences Team

And discover how we can support you in adapting your quality management system for your medical device or IVD in China.

Request Proposal